Mazdutide GLP-1 Research Peptide 10mg Lyophilized Vial CAS 2259884-03-0 hot selling
4 Inquiries
2259884-03-0
ep
99%
HongKong
10mg/vial
2026-11-04
Tirzepatide,Retatrutide,NAD+,Samaglutide,GHK-CU,cagrilintide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionMazdutide (also known as IBI362 or LY3305677), a novel once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, achieved 12-week body weight loss of up to 6.4% at doses up to 6 mg in Chinese adults with overweight or obesity. It is the first GLP-1R/GCGR dual agonist to succeed in Phase 3 trials. As mazdutide's first registrational trial for weight management, the results of GLORY-1 not only further confirm the efficacy and safety of the mazdutide in a large population but also provide high-quality clinical evidence of long-term pharmacotherapy weight management specifically for the Chinese population with overweight or obesity[1].Basic Info
-
Product Name:
Mazdutide
Other Name:Mazdutide;Mazdutide acetate;Mazdutide 10mg;Mazdutide 5mg 10mg;LY-3305677;Mazdutide (IBI-362;OXM-3)
CAS No.:2259884-03-0
Molecular Weight:0
EC Number:884-103-0
Color/Form:White to off-white
Categories:
Research-
Class:
Dual GLP-1R/GCGR agonist (long-acting peptide)
Status:Investigational — Phase 3 (China)
Mechanism:A long-acting dual agonist of the GLP-1 receptor (GLP-1R, Ki = 28.6 nM) and glucagon receptor (GCGR, Ki = 17.7 nM). The dual activation provides both glycemic control (via GLP-1R) and increased energy expenditure / hepatic lipolysis (via GCGR), producing weight loss beyond what GLP-1R agonism alone achieves. Administered once weekly.
EC50 (GLP1R Ki):28.6 nM
EC50 (GCGR Ki):17.7 nM
Source:GlpBio: Mazdutide (CAS 2259884-03-0); Innovent Phase Ib results (eClinicalMedicine 2022).DOI
Clinical Development:
References-
PubChem:Literature:
GlpBio: Mazdutide (CAS 2259884-03-0); eClinicalMedicine: Innovent Phase Ib results (2022); ClinicalTrials.gov: DREAMS-1 (NCT04930343)
Disclaimer:Mazdutide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials in China. This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Tirzepatide,Retatrutide,NAD+,Samaglutide,GHK-CU,cagrilintide
-
Location:
1502A1, Building 4, Xinyuanxin Center, No. 3 Huaxin Road, Dongfeng Street, Licheng District, Jinan City, Shandong Province
-
Payment Terms:
TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
1
-
Total Annual Revenue:
$10 million-$25 million
-
Total Employees:
51-100
-
Year of Establishment:
2026
-
Certifications:
COA,COA,COA,COA,COA,COA,COA,COA,COA,COA,COA,COA
-
-
Inquiry History4 Inquiries
Country Product Purchase Quantity Date Posted 
Nigeria
Mazdutide 10mg
20 PCS Mar 7, 2026 
United States
Mazdutide
30 MG Jul 15, 2024 
United Kingdom
Mazdutide
1 KG Feb 10, 2026
United States
Mazddultide cas
2 MT Nov 14, 2025 Post an enquiry for this product
